


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula I



in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A, SO₃H, SO₃A, -OSO₃H,
-OSO₃A, -OSO₂A, SO₂A, Hal, COOH, COOA, CONH₂, NHSO₂A,
COA, CHO or SO₂NH₂, or

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or
trisubstituted by A,

A is an unbranched or branched alkyl having 1-10 carbon atoms, in
which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

m is 1, 2, 3, 4 or 5, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

2. (Original) A compound according to Claim 1,

in which

R is -OH or -OA, and

X is OH, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

3. (Original) A compound according to Claim 1,
in which

R is -OH or -OA,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

4. (Original) A compound according to Claim 1,
in which

R is -OH or -OA, or

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or


a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

5. (Original) A compound according to Claim 1 selected from
5-hydroxy-2-(2',4'-dihydroxybenzoyl)chromone,
5-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone,
6-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or
6,7-methylenedioxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.


6. (Original) A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof comprising

- a) reacting a compound of formula II




in which

X and n are as defined in Claim 1,
with a compound of formula III




in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
to give a compound of formula IV




in which X and n are as defined in Claim 1, and A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

- b) then hydrolysing the compound of formula IV to a compound of formula V




in which X and n are as defined in Claim 1,

- c) then converting the compound of formula V to a compound of formula VI



in which X and n are as defined in Claim 1,

and then reacting the compound of formula VI with a compound of formula VII



in which R and m are as defined in Claim 1,

in a Friedel-Crafts acylation to give a compound of the formula I,

and/or

- d) a compound of formula I is converted into a salt or into a solvate and/or a stereoisomer of a compound of formula I is isolated.

7. (Original) A pharmaceutical composition comprising a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.
8. (Original) A method of inhibiting tyrosine kinase comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
9. (Original) A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
10. (Original) A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.
11. (Original) A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.
12. (Original) A method of treating a disease by inhibiting angiogenesis in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
13. (Original) A method according to Claim 12, wherein the disease is an ocular disease.
14. (Original) A method of treating retinal vascularisation in a mammal

comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.


15. (Original) A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
16. (Original) A method of treating an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
17. (Original) A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
18. (Original) A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.
19. (Original) A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
20. (Original) A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
21. (Original) A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.
22. (Original) A pharmaceutical composition according to claim 7, further

comprising an additional pharmaceutically active compound.

23. (Original) A kit comprising separate packs of
 - (a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,
and
 - (b) an additional pharmaceutically active compound or composition.
24. (Original) A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.
25. (Original) A method according to claim 24, further comprising performing radiotherapy on said mammal.
26. (Original) A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
27. (Original) A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.
28. (Original) A food supplement comprising a compound of claim 1.
29. (Original) A cosmetic composition comprising a compound of claim 1.
30. (Original) A method of protecting the proteins of the skin from stress

comprising applying a cosmetic composition of claim 29 to the skin.

31. (Original) A topically applicable cosmetic composition comprising a compound of claim 1.
32. (Currently Amended) A cosmetic composition ~~according to claim 29~~, containing 0.0001 to 50% by weight of a compound of claim 1.
33. (Original) A compound of formula VI



in which

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy, and

n is 1, 2, 3 or 4, or a

salt thereof.